[Pharmacological management of rheumatoid arthritis

the state of the art and the future perspective].

Hideto Kameda, Tsutomu Takeuchi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pharmacological management of rheumatoid arthritis (RA) has been rapidly progressed in recent years, which is appeared in the "treat to target" movement and the recommendations developed by some established international/domestic rheumatology associations. The baseline evaluation of poor prognostic factors as well as disease activity with composite measures is necessary for a personalized management. Methotrexate is currently the anchor drug, and other conventional or biological antirheumatic drugs should be added to it for refractory patients. The development of various novel agents including signal transduction inhibitors should promote further advances in the management of RA and other systemic autoimmune and/or inflammatory diseases.

Original languageEnglish
Pages (from-to)1166-1171
Number of pages6
JournalNihon rinsho. Japanese journal of clinical medicine
Volume71
Issue number7
Publication statusPublished - 2013 Jul
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Pharmacology
Antirheumatic Agents
Rheumatology
Methotrexate
Signal Transduction
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{9c201388946a47f9977fba5bc4c0c523,
title = "[Pharmacological management of rheumatoid arthritis: the state of the art and the future perspective].",
abstract = "Pharmacological management of rheumatoid arthritis (RA) has been rapidly progressed in recent years, which is appeared in the {"}treat to target{"} movement and the recommendations developed by some established international/domestic rheumatology associations. The baseline evaluation of poor prognostic factors as well as disease activity with composite measures is necessary for a personalized management. Methotrexate is currently the anchor drug, and other conventional or biological antirheumatic drugs should be added to it for refractory patients. The development of various novel agents including signal transduction inhibitors should promote further advances in the management of RA and other systemic autoimmune and/or inflammatory diseases.",
author = "Hideto Kameda and Tsutomu Takeuchi",
year = "2013",
month = "7",
language = "English",
volume = "71",
pages = "1166--1171",
journal = "Nihon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "7",

}

TY - JOUR

T1 - [Pharmacological management of rheumatoid arthritis

T2 - the state of the art and the future perspective].

AU - Kameda, Hideto

AU - Takeuchi, Tsutomu

PY - 2013/7

Y1 - 2013/7

N2 - Pharmacological management of rheumatoid arthritis (RA) has been rapidly progressed in recent years, which is appeared in the "treat to target" movement and the recommendations developed by some established international/domestic rheumatology associations. The baseline evaluation of poor prognostic factors as well as disease activity with composite measures is necessary for a personalized management. Methotrexate is currently the anchor drug, and other conventional or biological antirheumatic drugs should be added to it for refractory patients. The development of various novel agents including signal transduction inhibitors should promote further advances in the management of RA and other systemic autoimmune and/or inflammatory diseases.

AB - Pharmacological management of rheumatoid arthritis (RA) has been rapidly progressed in recent years, which is appeared in the "treat to target" movement and the recommendations developed by some established international/domestic rheumatology associations. The baseline evaluation of poor prognostic factors as well as disease activity with composite measures is necessary for a personalized management. Methotrexate is currently the anchor drug, and other conventional or biological antirheumatic drugs should be added to it for refractory patients. The development of various novel agents including signal transduction inhibitors should promote further advances in the management of RA and other systemic autoimmune and/or inflammatory diseases.

UR - http://www.scopus.com/inward/record.url?scp=84886581572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886581572&partnerID=8YFLogxK

M3 - Article

VL - 71

SP - 1166

EP - 1171

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 7

ER -